source
- Nouscom secures €120M to advance off-the-shelf cancer vaccine for Lynch syndromeSwiss biotech Nouscom announced a €120 million (about $135 million) Series D financing round. The capital will fund a registration-enabling pivotal trial of its cancer-preventing vaccine candidate.…
- Ambrose Healthcare acquires AM-Pharma for up to €161 millionAmbrose Healthcare, a British rare‑disease specialist, announced it has completed the acquisition of Dutch biotech AM‑Pharma. The deal values the company at up to 161 million euros (about $181 mill…